Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has scheduled a video webcast for June 2, 2025, at 8:00 a.m. ET to present results from their Phase 1 clinical trial of KT-621. The trial evaluated single and multiple-ascending doses of KT-621 in healthy volunteers. The company, which focuses on developing oral small molecule degrader medicines for immunological diseases, will make the presentation available through their website, with a replay and copy of the presentation accessible afterward. Interested parties can register for the webcast through a provided link or access it through the Investors section of Kymera's website.

Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025

WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event. 

About STAT6 and KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to provide the convenience of an oral medicine with the potential for biologics-like activity and in doing so reach broader patient populations compared to injectable biologics or other standards of care. In preclinical studies, KT-621 demonstrated dupilumab-like activity in several in vitro and in vivo models and was safe and well tolerated. KT-621, the first STAT6 directed medicine to enter clinical evaluation, has the opportunity to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Th2 diseases such as AD, asthma, chronic obstructive pulmonary disease (COPD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), bullous pemphigoid (BP), and chronic spontaneous urticaria (CSU), among others.

KT-621 is currently being evaluated in a Phase 1b trial (BroADen) in atopic dermatitis patients, with data from the study expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. 

Availability of Other Information About Kymera Therapeutics 
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. 

Investor and Media Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

When will Kymera Therapeutics (KYMR) announce KT-621 Phase 1 trial results?

Kymera Therapeutics will announce KT-621 Phase 1 trial results on Monday, June 2, 2025, at 8:00 a.m. ET via a video webcast.

What is the purpose of Kymera's KT-621 Phase 1 trial?

The Phase 1 trial evaluated single and multiple-ascending doses of KT-621 in healthy volunteers to assess the drug's safety and tolerability.

How can investors access Kymera's KT-621 Phase 1 results presentation?

Investors can access the presentation by registering through the provided link or visiting the 'News and Events' section in the Investors area of www.kymeratx.com.

What type of medicines is Kymera Therapeutics (KYMR) developing?

Kymera Therapeutics is developing a new class of oral small molecule degrader medicines specifically for immunological diseases.